Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 8/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2653551 | 0.88 | FGFR1 (0.46) | HPGDFGFR1SRC | |
| SCHEMBL2655147 | 0.85 | FGFR1 (0.43) | RAB9AKDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL2656192 | 0.84 | IDO1 (0.49) | RAB9AKDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL2659981 | 0.83 | KMT2A (0.41) | RAB9AKDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL2659773 | 0.83 | FGFR1 (0.42) | RAB9AKDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL2660553 | 0.82 | FGFR1 (0.47) | RAB9AKDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL2647252 | 0.81 | FGFR1 (0.62) | RAB9AALDH1A1HPGDSMN1; SMN2IDO1 | |
| SCHEMBL2653400 | 0.81 | FGFR1 (0.47) | RAB9AKDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL20510883 | 0.81 | FGFR1 (0.58) | HTTIDO1FGFR1CYP11B1CYP11B2 | |
| SCHEMBL2659276 | 0.80 | HPGD (0.38) | RAB9AKDM4EALDH1A1HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060069135-A1 | Benzimidazole derivatives and their use for modulating the gaba-a receptor complex | NEUROSEARCH A/S (DK) | 2006-03-30 | — | — | US | claimed |
| CN-1759112-A | Benzimidazole derivatives and their use for modulating the GABA- SB A /SB receptor complex | NEUROSEARCH AS (DK) | 2006-04-12 | — | — | CN | disclosed |
| US-20060069135-A1 | Benzimidazole derivatives and their use for modulating the gaba-a receptor complex | NEUROSEARCH A/S (DK) | 2006-03-30 | — | — | US | disclosed |
| EP-1613618-A2 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABA- sb A /sb RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004087690-A2 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABA-A RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069135-A1 | Benzimidazole derivatives and their use for modulating the gaba-a receptor complex | GABRB2, GABRB1, GABRB3 | RAB9A 2329/4885KDM4E 1815/4885ALDH1A1 477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.